Semaglutide Clinical Trial Protocol to Map Hepatic Glucose Response in Non-Alcoholic Fatty Liver Disease
Background
Non-alcoholic fatty liver disease (NAFLD) is a prevalent global hepatopathy characterized by fat accumulation in the liver, potentially progressing to non-alcoholic steatohepatitis (NASH), cirrhosis, or hepatocellular carcinoma. Driven by rising rates of obesity and type 2 diabetes mellitus, NAFLD-related cirrhosis has become a leading cause of liver failure in developed nations. Current standard-of-care often involves lifestyle modifications, but effective pharmacological interventions targeting the underlying mechanisms of liver damage are still needed. Understanding the liver's specific response to feeding in NAFLD patients, and how this is modulated by drugs like semaglutide, is crucial for developing targeted therapies.
Study Design
The NAFLD HEROES study is a clinical trial designed to investigate the liver's response to feeding in NAFLD patients and the effect of semaglutide. Participants, including those with NAFLD and healthy volunteers (ages 18+), undergo initial screening with medical history, physical exam, blood tests, and imaging. NAFLD participants also receive a liver and fatty tissue biopsy. Following screening, participants have multi-day clinic stays involving comprehensive blood, urine, heart, and imaging tests. NAFLD participants then begin semaglutide treatment, administered as a once-weekly injection at home, with follow-up visits at weeks 1, 2, 4, 8, 12, 16, 20, and 24. A final clinic stay at week 30 repeats baseline tests, followed by a final visit 12 weeks post-treatment cessation.
Results
This abstract details the comprehensive protocol for the NAFLD HEROES clinical trial, outlining its objectives and methodology. The study aims to elucidate how the liver in individuals with NAFLD responds to feeding and how this response is influenced by semaglutide treatment. No results from the study are presented in this document, as it focuses solely on the design and planned execution of the research. The detailed protocol includes specific timelines for participant visits, diagnostic procedures, and treatment administration, setting the stage for future data collection and analysis. The primary objective is stated as:
To find out how the liver in people with NAFLD responds to feeding, and how this relates to their response to the drug semaglutide.
Why It Matters
This detailed protocol for the NAFLD HEROES trial is significant because it outlines a robust investigation into semaglutide's potential role in managing NAFLD by understanding its impact on hepatic glucose response. For peptide users and clinicians, this study could provide critical insights into how GLP-1 receptor agonists influence liver metabolism in a disease with limited treatment options. Understanding the specific metabolic changes induced by semaglutide in NAFLD patients could inform future dosing strategies or combination therapies. If positive findings emerge, this research could pave the way for semaglutide's broader application in NAFLD, potentially shifting clinical practice towards earlier intervention with GLP-1R agonists. The protocol's depth suggests a thorough approach to uncovering the mechanisms by which semaglutide might improve liver health, moving beyond just weight loss.
semaglutide
non-alcoholic-fatty-liver-disease
nafld
hepatic-steatosis
glucose-metabolism
clinical-trial
